Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, December 9 at 2:00 PM ET

Register Free →

This Subcontract opportunity from Department Of Health And Human Services was posted on January 16, 2025. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Monoclonal Antibody Therapeutic Development for Pandemic Viruses

Closed
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

AI Contract Overview

Show more

The National Institutes of Health NIAID, under the Department of Health and Human Services, is seeking a subcontractor for the Monoclonal Antibody Therapeutic Development for Pandemic Viruses project. This initiative focuses on the research, design, and advancement of monoclonal antibody candidates specifically targeting viruses with pandemic potential, while ensuring all work remains compliant with exclusions regarding full-length proteins. Interested parties must submit their responses by February 21, 2025, at 8:00 PM. The opportunity is categorized under NAICS code 541711, reflecting its focus on research and development in the biotechnology sector.

General Info

NAICS

541711 - Research and Development in Biotechnology

Place of Performance

MD

Set-Aside

NONE

Documents

This scope was carved out of HHS-NIH-NIAID-BAA2025-1.

The full solicitation package (8 documents), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

2026 NIAID DMID Omnibus Broad Agency Announcement

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed
Posted

subcontract

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Niaid
ContactsNo contacts available
OfficeN/A
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Research, design, and advance monoclonal antibody candidates targeting pandemic-prone viruses, compliant with exclusions on full-length proteins.

More opportunities from Department Of Health And Human Services → National Institutes Of Health Niaid

Same awarding agency

NAICS: 541715
Federal
2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases
Solicitation # HHS-NIH-NIAID-BAA2026-1
The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting proposals under Broad Agency Announcement HHS-NIH-NIAID-BAA2026-1 to advance medical interventions for infectious diseases. The initiative focuses on three primary research areas: the development of needle-free vaccine candidates through early phase clinical trials for viral pathogens; the creation of safe and effective therapeutic products for serious infectious diseases that are currently untreatable or drug-resistant; and the innovation of in vitro diagnostic technology platforms capable of rapid, point-of-care detection of priority viral families. For Fiscal Year 2027, NIAID estimates a total award amount of up to 16 million dollars for the non-severable base awards, with the potential for cost-reimbursement contracts lasting up to five years. Proposals must be submitted electronically via the eCPS portal by December 8, 2026, at 3:00 PM Eastern Time. Technical proposals are limited to 75 pages and will be evaluated by a peer review group based on scientific and technical merit, which is the paramount consideration for award. While cost is a factor, it is significantly less important than technical acceptability. Awardees will be required to adhere to Good Manufacturing Practice (GMP) for drug products and comply with HHS Section 508 accessibility standards. Key personnel must be named in the award, and a mandatory kick-off meeting is required within 60 days of the effective award date.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

10 days ago

DEADLINE

in 24 days
View Details

Earlier notices in this NAICS code

Posted before this notice, open and closed

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS